NO953279L - Transmucosal levering av makromolekylære medikamenter - Google Patents

Transmucosal levering av makromolekylære medikamenter

Info

Publication number
NO953279L
NO953279L NO953279A NO953279A NO953279L NO 953279 L NO953279 L NO 953279L NO 953279 A NO953279 A NO 953279A NO 953279 A NO953279 A NO 953279A NO 953279 L NO953279 L NO 953279L
Authority
NO
Norway
Prior art keywords
macromolecular
polymer
drug
enhancer
macromolecular drugs
Prior art date
Application number
NO953279A
Other languages
English (en)
Other versions
NO953279D0 (no
Inventor
Sonia J Heiber
Charles D Ebert
Sirish C Dave
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Publication of NO953279D0 publication Critical patent/NO953279D0/no
Publication of NO953279L publication Critical patent/NO953279L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En fremgangsmåte og et system for mukosal administrering av et makromolekylært medikament til slimhinnen i oralhulrommet er vist. Systemet omfatter et indre medikament/enhancer/polymerlag (11) som har en overflate tilpasset for å kontakte og adherere til slimhinnevevet i oralhulrommet og en motstående overflate i kontakt med og adhererende til et overliggende inert lag (12). Det indre laget (11) inneholder fra omtrent to til seksti vekt-% av en gallesaltenhancer, 5 til 65 vekt-% av en hydrofil polymer som er vannoppløselig eller svellbar og en effektiv mengde av et makromolekylært medikament som har en molekylvekt på minst 500 dalton. Polysaccharider, polypeptider og proteiner er foretrukne former for makromolekylære medikamenter. Gallesaltenhanceren letter leveringen av makromolekyler slik som lav molekylært heparin og kalsitonin. Polymeren virker som et plastifiserende middel for å forhindre krystallisering og/eller agregering av slike makromolekylære medikamenter. Hydroksypropylcellulose er en spesielt egnet polymer.
NO953279A 1993-02-22 1995-08-21 Transmucosal levering av makromolekylære medikamenter NO953279L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,508 US5346701A (en) 1993-02-22 1993-02-22 Transmucosal delivery of macromolecular drugs
PCT/US1994/001372 WO1994018925A1 (en) 1993-02-22 1994-02-03 Transmucosal delivery of macromolecular drugs

Publications (2)

Publication Number Publication Date
NO953279D0 NO953279D0 (no) 1995-08-21
NO953279L true NO953279L (no) 1995-10-19

Family

ID=21838122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953279A NO953279L (no) 1993-02-22 1995-08-21 Transmucosal levering av makromolekylære medikamenter

Country Status (16)

Country Link
US (2) US5346701A (no)
EP (1) EP0684806B1 (no)
JP (1) JP2795749B2 (no)
KR (1) KR960700670A (no)
AT (1) ATE190216T1 (no)
AU (1) AU674571B2 (no)
CA (1) CA2156708C (no)
DE (1) DE69423342T2 (no)
DK (1) DK0684806T3 (no)
ES (1) ES2148320T3 (no)
GR (1) GR3033601T3 (no)
HK (1) HK1010680A1 (no)
NO (1) NO953279L (no)
PT (1) PT684806E (no)
WO (1) WO1994018925A1 (no)
ZA (1) ZA941197B (no)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464866A (en) * 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
WO1996013270A1 (en) * 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Heparin, compositions and methods of use therefore
US6992107B1 (en) * 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
JP2001517493A (ja) * 1997-09-26 2001-10-09 ノーヴェン ファーマシューティカルズ インコーポレイテッド 生体接着剤組成物及び活性薬剤の局所投与方法
US20040018241A1 (en) * 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
JP4523153B2 (ja) 1998-03-19 2010-08-11 ブリストル−マイヤーズ スクイブ カンパニー 易溶性薬物の二層性放出制御送達システムおよび方法
CA2337823A1 (en) * 1998-06-26 2000-01-06 Bernard Meignier Mucosal targeting immunisation
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
EP1113801A4 (en) 1998-09-17 2002-10-02 Bristol Myers Squibb Co METHOD FOR TREATING ATHEROSCLEROSIS WITH AN AP2 INHIBITOR OR COMBINATION
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
ATE273698T1 (de) * 1998-10-02 2004-09-15 3M Innovative Properties Co Systeme zur arzneistoffabgabe an schleimhäute
DE19856101A1 (de) * 1998-12-04 2000-06-08 Labtec Gmbh Mundhöhlen-Matrixpflaster
CA2358054C (en) * 1998-12-28 2008-11-18 Allergy Limited, Llc Cyanocobalamin (vitamin b12) treatment in allergic disease
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6180682B1 (en) 1999-01-26 2001-01-30 Virgil A. Place Buccal drug delivery system for use in male contraception
US6284262B1 (en) 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6353770B1 (en) 1999-05-26 2002-03-05 Levi Strauss & Co. Apparatus and method for the remote production of customized clothing
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
DE10026699A1 (de) * 2000-05-30 2001-12-06 Basf Ag Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
US6756051B1 (en) 2000-11-15 2004-06-29 Li-Lan H. Chen Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
HUP0600232A2 (en) 2001-04-11 2006-08-28 Bristol Myers Squibb Co Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
CN1531436A (zh) * 2001-05-09 2004-09-22 (株)美大富历寿 用于增强粘膜吸收的两亲肝素衍生物制剂
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US7357891B2 (en) * 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20100021526A1 (en) * 2001-10-12 2010-01-28 Monosol Rx, Llc Ph modulated films for delivery of actives
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) * 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20070154527A1 (en) * 2001-10-12 2007-07-05 Monosoirx, Llc Topical film compositions for delivery of actives
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US7666337B2 (en) * 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7910641B2 (en) * 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US6806381B2 (en) * 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
AU2002348276A1 (en) * 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
US8017150B2 (en) * 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
KR101069781B1 (ko) * 2002-05-14 2011-10-05 프라샌트 인베스트먼츠, 엘엘씨 전송 신호를 생성하는 방법
BR0311530A (pt) * 2002-05-23 2005-05-10 Umd Inc Compostos e método de liberação para droga transmucosal e para crio-proteção
DE60332856D1 (de) * 2002-10-23 2010-07-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
WO2004066929A2 (en) * 2003-01-24 2004-08-12 Bristol-Myers Squibb Company Cycloalkyl containing anilide ligands for the thyroid receptor
TW200504021A (en) * 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7306812B2 (en) * 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US20040241223A1 (en) * 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
KR20060012661A (ko) * 2003-06-04 2006-02-08 캔지, 인크. 인터페론 요법을 위한 방법 및 조성물
US7459474B2 (en) * 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DK1695094T3 (da) 2003-10-24 2013-09-16 Adhesives Res Inc Disintegrerende film til diagnostiske indretninger
CA2545311C (en) * 2003-11-12 2012-01-03 Phenomix Corporation Heterocyclic boronic acid compounds
US7767828B2 (en) * 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) * 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) * 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
JP2008505975A (ja) * 2004-07-12 2008-02-28 フェノミックス コーポレーション 制約されたシアノ化合物
JP2008511651A (ja) * 2004-08-30 2008-04-17 セオ ホン ユー 局所虚血モデルでの可溶化ｕｄｃａの神経保護効果
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
KR20070084211A (ko) * 2004-10-15 2007-08-24 유서홍 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물
KR101358078B1 (ko) * 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
US7589088B2 (en) * 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) * 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7825139B2 (en) * 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007053819A2 (en) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
CA2636026A1 (en) * 2006-01-20 2007-07-26 Monosol Rx, Llc Film lined pouch and method of manufacturing this pouch
US20070238770A1 (en) * 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
ES2426445T3 (es) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
EP2040731A4 (en) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN103550136B (zh) * 2006-07-21 2016-04-13 生物递送科学国际公司 吸收增强的经粘膜递送装置
CN101516331A (zh) * 2006-09-20 2009-08-26 莫诺索尔克斯有限公司 含有抗泡沫调味剂的可食用水溶性膜
CA2664615A1 (en) * 2006-09-29 2008-04-10 Monosol Rx, Llc Film embedded packaging and method of making same
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
CN101573340A (zh) 2006-11-01 2009-11-04 百时美施贵宝公司 糖皮质激素受体AP-1和/或NF-κB活性的调节剂及其用途
US7994190B2 (en) 2006-11-01 2011-08-09 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US20100086495A1 (en) * 2007-02-15 2010-04-08 Derma-Young Ltd. Compositions and methods for enhancing transmucosal delivery
AU2008262490B2 (en) * 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2008651A1 (en) * 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
EP2209780B1 (en) 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
TW200950801A (en) * 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of peptides and processes of preparation thereof
JP2011525536A (ja) * 2008-06-23 2011-09-22 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド 多方向性粘膜送達装置および使用法
WO2009158380A1 (en) 2008-06-24 2009-12-30 Bristol-Myers Squibb Company Cyclopentathiophene modulators of the glucocorticoid receptor, ap-1, and/or nf-kappa b activity and use thereof
JP2012518686A (ja) * 2009-02-25 2012-08-16 メリオン・リサーチ・Ｉｉｉ・リミテッド ビスホスホネート類の組成物および薬物送達
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US9421169B2 (en) 2009-11-20 2016-08-23 Covidien Lp Oral dosage forms for delivery of therapeutic agents
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2011137491A1 (en) * 2010-05-06 2011-11-10 University Of South Australia Novel drug delivery system
JP5819949B2 (ja) 2010-06-10 2015-11-24 ミダテック リミテッド ナノ粒子フィルム送達システム
RU2016125229A (ru) 2010-07-09 2018-12-04 БиЭйчВи ФАРМА, ИНК. Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
CA2830065A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
ES2660116T3 (es) 2011-08-18 2018-03-20 Biodelivery Sciences International, Inc. Dispositivos mucoadhesivos resistentes al uso inadecuado para la administración de buprenorfina
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
JP2019519487A (ja) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド 送達増強エピネフリン組成物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US20230201315A1 (en) 2020-01-03 2023-06-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Tnap locally administered for promoting periodontal health
WO2023027006A1 (ja) * 2021-08-27 2023-03-02 学校法人東京理科大学 膜透過促進剤、膜透過促進方法、及び細胞内送達方法
WO2023064255A2 (en) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnosis and treatment of anti-pf4 induced thrombocytopenia
WO2023200897A1 (en) 2022-04-13 2023-10-19 The Regents Of The University Of California Use of viral il-6 in cancer therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772470A (en) * 1985-04-27 1988-09-20 Nitto Electric Industrial Co., Ltd. Oral bandage and oral preparations
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4948580A (en) * 1988-12-08 1990-08-14 E. R. Squibb & Sons, Inc. Muco-bioadhesive composition
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5122383A (en) * 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs

Also Published As

Publication number Publication date
DE69423342T2 (de) 2000-10-12
EP0684806A4 (en) 1997-04-23
PT684806E (pt) 2000-08-31
NO953279D0 (no) 1995-08-21
GR3033601T3 (en) 2000-10-31
CA2156708A1 (en) 1994-09-01
AU6171694A (en) 1994-09-14
EP0684806B1 (en) 2000-03-08
DE69423342D1 (de) 2000-04-13
JPH08507759A (ja) 1996-08-20
CA2156708C (en) 2005-05-03
ES2148320T3 (es) 2000-10-16
WO1994018925A1 (en) 1994-09-01
ZA941197B (en) 1994-09-19
HK1010680A1 (en) 1999-06-25
KR960700670A (ko) 1996-02-24
US5516523A (en) 1996-05-14
US5346701A (en) 1994-09-13
ATE190216T1 (de) 2000-03-15
EP0684806A1 (en) 1995-12-06
JP2795749B2 (ja) 1998-09-10
DK0684806T3 (da) 2000-08-14
AU674571B2 (en) 1997-01-02

Similar Documents

Publication Publication Date Title
NO953279L (no) Transmucosal levering av makromolekylære medikamenter
EP0460020B2 (en) Drug delivery compositions
US5554388A (en) Systemic drug delivery compositions comprising a polycationi substance
Bernkop-Schnürch et al. Polymers with thiol groups: a new generation of mucoadhesive polymers?
EP1722759B1 (en) Composition containing chitosan and a polyol-phosphate or a sugar-phosphate
AU2006327277B2 (en) Water-soluble films comprising low-viscosity alginates
EP0302772B1 (en) Calcitonin composition for nasal administration
CN1230203C (zh) 粘膜粘附聚合物,其应用及其制备方法
JP2009029824A (ja) ペクチンのインサイチュゲル化
JPH06107550A (ja) 経口抗炎症剤
AU1469295A (en) Low molecular weight hyaluronic acid with peptide or protein
Bernkop-Schnürch et al. Thiomers: The next generation of mucoadhesive polymers
Sandri et al. Mucoadhesive polymers as enabling excipients for oral mucosal drug delivery
Nakanishi et al. Use of sodium salt of Carbopol 934P in oral peptide delivery
Rao et al. Bioadhesion and Factors Affecting the Bioadhesion of Microparticles 1
US20030176394A1 (en) Pepsin inhibition by alginates
Vetter et al. Bioadhesive Delivery Systems
CA1297627C (en) Biologically degradable polymers for depot preparations havingcontrolled release of the active compound
Vetter et al. 14 Bioadhesive Delivery Systems
BR102018012321A2 (pt) composição de um sistema biopolimérico para veiculação oral de fármacos proteicos
CA2179294A1 (en) Low molecular weight hyaluronic acid with peptide or protein

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application